drugset / Trial / NCT01662102
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effect of consolidation treatment Zevalin® versus maintenance treatment with Rituxan® on progression-free survival (PFS) following response induction with chemotherapy plus rituximab in previously untreated participants with follicular lymphoma.
Timeline
- Start
- 2012-12-11
- Primary completion
- 2013-03-05
- Completion
- 2013-03-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | ibritumomab tiuxetan | Monoclonal antibody | 0.3 unknown | Intravenous |
| Subject | ibritumomab tiuxetan | Monoclonal antibody | 14.8 mbq/kg | Intravenous |